Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (481)	8/17/1999 3:39:00 PM
From: squetch	Read Replies (1) \| Respond to of 717

Not that this is a big deal, I noticed >>PHARMACYCLICS(R), our pentadentate logo, ANTRIN(R), LUTRIN(R), OPTRIN(TM) and XCYTRIN(TM) are trademarks of Pharmacyclics, Inc. CITRA VU(TM) is the trademark of E-Z-EM, Inc. for the oral contrast agent it has licensed from Pharmacyclics, Inc.<< The name Gadolite doesn't appear in the S-3. E-Z-EM has another product trademarked soft-vu, but I didn't find citra-vu in USPTO.

To: scaram(o)uche who wrote (481)	8/18/1999 11:17:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 717

biz.yahoo.com Wednesday August 18, 10:38 am Eastern Time Company Press Release SOURCE: QLT PhotoTherapeutics Inc. QLT and CIBA Vision announce regulatory submission seeking approval of Visudyne for AMD in Switzerland ATLANTA, GA AND VANCOUVER, Aug. 18 /CNW-PRN/ - CIBA Vision Corporation, the eye care unit of Novartis AG, and QLT PhotoTherapeutics Inc. today announced the filing of Visudyne(TM) therapy with the Swiss regulatory agency, Interkantonale Kontrollstelle fur Heilmittel (IKS) for the treatment of wet (snip)